NEW YORK (GenomeWeb News) – Genomind today announced a partnership with Emory University to commercialize a blood-based screening test for mild cognitive impairment and Alzheimer's disease.

Under the terms of the deal, Genomind has attained the exclusive rights to commercialize blood-based protein biomarkers for assessment of the conditions. Other terms of the agreement were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.